MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
AIkido Pharma Net Income 2011-2026 | AIKI
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income AIkido Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -14.7 M | -22.9 M | -22.1 M | -7.17 M | -12.3 M | -4.18 M | 1.73 M | -3.31 M | -6.48 M | -51.5 M | -30.5 M | -18 M | - | -3.46 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.73 M | -51.5 M | -15.5 M |
Quarterly Net Income AIkido Pharma
| 2025-Q3 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125 M | - | -4.21 M | -6.12 M | -5.44 M | - | -3.54 M | -8.66 M | -3.76 M | - | -6.24 M | -5.08 M | -3.54 M | - | -47 K | -1.35 M | -3.96 M | - | -2.02 M | -2.31 M | -8.33 M | - | -3.36 M | -644 K | -1.15 M | - | -1.89 M | -398 K | -1.49 M | - | 459 K | -1.86 M | -919 K | - | -446 K | -2.08 M | -49 K | - | -2.73 M | -40.3 M | -4.09 M | - | -5.14 M | -11.6 M | -7.96 M | - | -9.28 M | -807 K | -3.7 M | - | -708 K | -405 K | -834 K | - | -913 K | -1.01 M | -235 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 125 M | -40.3 M | -998 K |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K |  USA |
 |
AbbVie
ABBV
|
1.82 B | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
-146 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Grifols, S.A.
GRFS
|
265 M | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-18.5 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Cocrystal Pharma
COCP
|
-8.83 M | $ 1.51 | 48.04 % | $ 17 M | USA |
 |
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 55.5 | -3.04 % | $ 10.6 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-65.8 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
-88.1 M | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
7.71 B | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
211 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Bristol-Myers Squibb Company
BMY
|
7.05 B | $ 59.6 | -2.45 % | $ 121 B | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
172 M | $ 4.14 | -2.59 % | $ 683 M | Britain |
 |
BioCryst Pharmaceuticals
BCRX
|
-88.9 M | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Avenue Therapeutics
ATXI
|
-2.91 M | - | -52.27 % | $ 4.45 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-158 M | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
12.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Cellectis S.A.
CLLS
|
-125 M | $ 3.41 | 1.19 % | $ 116 M | France |
 |
Biogen
BIIB
|
1.29 B | $ 177.34 | -3.5 % | $ 26 B | USA |
 |
Axcella Health
AXLA
|
-81.2 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 412.81 | -2.54 % | $ 31.3 B | USA |